$HIND

Vyome Holdings, Inc

Vyome Holdings is a clinical-stage specialty pharmaceutical company developing treatments for immune-inflammatory and rare diseases. Its biotechnology segment includes VT-1953, a topical gel in development for symptoms of malignant fungating wounds in advanced cancer; VT-1908, an ophthalmic drops program for anterior uveitis; and VB-1953, a program for moderate to severe acne. The company’s pharmaceutical segment comprises antifungal products developed using its Molecular Replacement Therapeutics platform, including a dandruff lotion and shampoo commercialized in India by Sun Pharma under a licensing and marketing agreement. Vyome receives a net service fee for sales of those products by Sun Pharma and has also agreed with Sun Pharma to develop and license an MRT-based luliconazole topical cream for the Indian market. Vyome is based in Cambridge, Massachusetts, Princeton, New Jersey, and New Delhi, India.

0
1
1

No SEC Form 4 filings for $HIND in the last 30 days.

See all $HIND insider activity →
Med

Vyome narrows Q3 loss to $0.13 per share, cash rises to $7M

Vyome Holdings (NASDAQ:HIND) reported a narrower Q3 loss of $0.13 per share, down from $3.06 a year ago. Revenue increased to $57,998 from $34,627, but nine-month revenue fell to $116,544. Cash rose to $6.96M. Operating expenses decreased to $1.05M. The company is developing VT-1953 and appointed a new CFO. The FDA requested more info on its orphan drug designation.

Vyome at Chardan healthcare conference: lean biotech bets on rare wounds

Vyome Therapeutics (HIND) presented its strategy at Chardan's healthcare conference, focusing on VT-1953, a topical gel for malignant fungating wounds. The company reported Q2 operating expenses of $874,000 and shared encouraging early data from a Phase II study. Vyome aims to conserve capital and targets rare diseases with unmet needs, engaging with the FDA for further discussions.

When it comes to rate hikes, CFOs aren't counting on a 'one-and-done'

The Fed updated projections, now seeing the federal funds rate at 4.1% by 2026, up from 3.8% in June, indicating another hike. CFOs face higher costs for floating-rate credit and new issuances. Yiming Ma, a finance professor, advises stress testing funding and production costs together. Markets reacted negatively, with Treasury yields rising. Vyome and Zelis appointed new CFOs. A report found 83% of executives made decisions based on outdated forecasts, with 40% facing significant consequences.

HIND sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning HIND (Vyome Holdings, Inc). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.

Recent HIND coverage spans earnings, financial news and macro economy.

What's driving HIND

  • The narrowed loss may provide modest upside pressure, but ongoing cash burn and low revenue keep risk elevated.

    investing.com · Nov 16, 2026

  • Vyome Therapeutics (HIND) presented its strategy at Chardan's healthcare conference, focusing on VT-1953, a topical gel for malignant fungating wounds. The company reported Q2 operating expenses of $874,000 and shared encouraging early data from a Phase II study. Vyome aims to conserve capital and targets rare diseases with unmet needs, engaging with the FDA for further discussions.

    investing.com · Oct 20, 2026

  • Neutral impact; CFO change may affect future financial strategy but no immediate market move.

    fortune.com · Sep 17, 2026

  • The CFO change is a routine corporate action with limited immediate price impact.

    SEC EDGAR 8-K · Aug 28, 2026

  • Positive Phase 2 outcomes and FDA feedback may boost near‑term valuation; cash runway remains limited.

    SEC EDGAR 8-K · Aug 25, 2026

AlphAI scores every news story that mentions HIND with an AI model for sentiment and relevance, and aggregates insider trades from Vyome Holdings, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $HIND

Score

Vyome narrows Q3 loss to $0.13 per share, cash rises to $7M

Vyome Holdings (NASDAQ:HIND) reported a narrower Q3 loss of $0.13 per share, down from $3.06 a year ago. Revenue increased to $57,998 from $34,627, but nine-month revenue fell to $116,544. Cash rose to $6.96M. Operating expenses decreased to $1.05M. The company is developing VT-1953 and appointed a new CFO. The FDA requested more info on its orphan drug designation.

HighAI 8/10

Vyome at Chardan healthcare conference: lean biotech bets on rare wounds

Vyome Therapeutics (HIND) presented its strategy at Chardan's healthcare conference, focusing on VT-1953, a topical gel for malignant fungating wounds. The company reported Q2 operating expenses of $874,000 and shared encouraging early data from a Phase II study. Vyome aims to conserve capital and targets rare diseases with unmet needs, engaging with the FDA for further discussions.

When it comes to rate hikes, CFOs aren't counting on a 'one-and-done'

The Fed updated projections, now seeing the federal funds rate at 4.1% by 2026, up from 3.8% in June, indicating another hike. CFOs face higher costs for floating-rate credit and new issuances. Yiming Ma, a finance professor, advises stress testing funding and production costs together. Markets reacted negatively, with Treasury yields rising. Vyome and Zelis appointed new CFOs. A report found 83% of executives made decisions based on outdated forecasts, with 40% facing significant consequences.

$HINDLowExec change· appointed

Vyome Holdings, Inc (HIND): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Vyome Holdings, Inc (HIND) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2026, the board of directors (the “Board”) of Vyome Holdings, Inc. (the “Company”) appointed Jerry Leonard as

$HINDHighEarnings

Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead VT-1953 Program, Pipeline Expansion And Strong Balance Sheet

Vyome Holdings, Inc (HIND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead VT-1953 Program, Pipeline Expansion And Strong Balance Sheet CAMBRIDGE, Mass., August 25, 2026 — Vyome Holdings, Inc. (“Vyome”), a clinical-stage biopharmaceutical company focused o

Related tickers